Collaboration accelerates TAG1’s Pb-212 generator development and supports PharmaLogic’s mission to scale radiopharmaceutical innovation.
TAG1 Inc., a premier supplier of clinical quantities of medical isotopes, announced a strategic partnership with PharmaLogic, a leading contract development and manufacturing organization specialized in radiopharmaceuticals. The collaboration marks a pivotal step forward in bringing TAG1’s proprietary Pb-212 generator platform broader market access and continuing Pharmalogic’s industry leading efforts in increasing the availability of alpha isotopes.
Health Technology Insights: PharmaLogic Completes Acquisition of Majority Stake in Agilera Pharma AS
Over the past 18 months, TAG1’s generator design has been rapidly prototyped and incubated at the Missouri University Research Reactor and MITC facilities. With the TAG1 Board formally approving the final clinical design, the company is now transitioning to scale-up and production, positioning itself to deliver reliable, high-purity Pb-212 through a decentralized, on-site generator model for radiopharmacies, hospitals, and therapeutic developers.
TAG1 begins scale-up to deliver high-purity Pb-212 via a decentralized, on-site generator model for clinical use
“This partnership with PharmaLogic is a defining step forward as we scale our Pb-212 generator technology,” said Sumit Verma, CEO and Founder of TAG1. “PharmaLogic’s operational strength and commitment to innovation make them an ideal partner as we move from concept to clinic with a solution that supports both emerging and established radiotherapeutic programs.”
Health Technology Insights: Sg2 Forecasts 18% Growth in Outpatient Care, 5% Inpatient Care
TAG1’s technology is designed to mirror established generator models in nuclear medicine by enabling on-demand, local production of Pb-212. This decentralized approach is critical to overcoming isotope supply bottlenecks and supporting the growing number of biopharma companies advancing Pb-212-based therapies across oncology and rare diseases.
“We’re thrilled to support TAG1’s next phase of growth and help expand access to alpha-emitting isotopes like Pb-212,” Etienne Montagut, President and CEO of PharmaLogic, added. “As the need for targeted radiotherapeutics continues to grow, strategic partnerships are essential to bridging innovation and clinical delivery.”
PharmaLogic brings extensive experience in radiopharmaceutical development, regulatory compliance, and commercial-scale manufacturing across North America. With a robust network of radiopharmacies and a proven CDMO model, PharmaLogic will provide operational support for TAG1’s transition from prototype to clinical-grade generator production.
The companies will continue working closely with pharmaceutical partners, academic institutions, and early innovators to deliver preclinical and clinical quantities of Pb-212 on demand, supporting the next wave of breakthroughs in targeted alpha therapy.
Health Technology Insights: CrowdCare Redefines Healthcare Access with Peer-Powered Alternative to Insurance
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
